Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells

Joon Jeong, Kyung Sun Lee, Yang Kyu Choi, Young Ju Oh, Hy De Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients with bone metastasis. We evaluated the effects of zoledronic acid, a third generation, nitrogen-containing bisphosphonate, to prevent bone metastasis in breast cancer. Zoledronic acid or vehicle alone was administered to nude mice either simultaneously or after intracardiac injection of human breast cancer MDA-MB-231 cells. Nude mice treated with zoledronic acid at early time points showed a lower incidence of bone metastases than did vehicle-treated nude mice, but these differences were not statistically significant. Only 37.5% of mice treated with zoledronic acid at the time of tumor cell inoculation developed bone metastases compared to over 51.8% of mice receiving vehicle alone (P = 0.304). Cell count of apoptosis confirmed by immunohistochemical staining in metastatic bone tissue significantly increased in the zoledronic acid-treated groups compared to non-treated group (1,018.3 vs 282.0; P = 0.046). However, metastatic tumor cells, which invade soft tissue around the bone, did not show extensive apoptosis; there were no differences between the zoledronic acid-treated and control groups. These results suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in the bone and could therefore reduce metastatic tumor burden. These results support the use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.

Original languageEnglish
Pages (from-to)1569-1575
Number of pages7
JournalJournal of Korean medical science
Volume26
Issue number12
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

zoledronic acid
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Nude Mice
Diphosphonates
Apoptosis
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Jeong, Joon ; Lee, Kyung Sun ; Choi, Yang Kyu ; Oh, Young Ju ; Lee, Hy De. / Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells. In: Journal of Korean medical science. 2011 ; Vol. 26, No. 12. pp. 1569-1575.
@article{438f4f8c72fd460c9611d63482aaba9c,
title = "Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells",
abstract = "Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients with bone metastasis. We evaluated the effects of zoledronic acid, a third generation, nitrogen-containing bisphosphonate, to prevent bone metastasis in breast cancer. Zoledronic acid or vehicle alone was administered to nude mice either simultaneously or after intracardiac injection of human breast cancer MDA-MB-231 cells. Nude mice treated with zoledronic acid at early time points showed a lower incidence of bone metastases than did vehicle-treated nude mice, but these differences were not statistically significant. Only 37.5{\%} of mice treated with zoledronic acid at the time of tumor cell inoculation developed bone metastases compared to over 51.8{\%} of mice receiving vehicle alone (P = 0.304). Cell count of apoptosis confirmed by immunohistochemical staining in metastatic bone tissue significantly increased in the zoledronic acid-treated groups compared to non-treated group (1,018.3 vs 282.0; P = 0.046). However, metastatic tumor cells, which invade soft tissue around the bone, did not show extensive apoptosis; there were no differences between the zoledronic acid-treated and control groups. These results suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in the bone and could therefore reduce metastatic tumor burden. These results support the use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.",
author = "Joon Jeong and Lee, {Kyung Sun} and Choi, {Yang Kyu} and Oh, {Young Ju} and Lee, {Hy De}",
year = "2011",
month = "12",
day = "1",
doi = "10.3346/jkms.2011.26.12.1569",
language = "English",
volume = "26",
pages = "1569--1575",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "12",

}

Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells. / Jeong, Joon; Lee, Kyung Sun; Choi, Yang Kyu; Oh, Young Ju; Lee, Hy De.

In: Journal of Korean medical science, Vol. 26, No. 12, 01.12.2011, p. 1569-1575.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells

AU - Jeong, Joon

AU - Lee, Kyung Sun

AU - Choi, Yang Kyu

AU - Oh, Young Ju

AU - Lee, Hy De

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients with bone metastasis. We evaluated the effects of zoledronic acid, a third generation, nitrogen-containing bisphosphonate, to prevent bone metastasis in breast cancer. Zoledronic acid or vehicle alone was administered to nude mice either simultaneously or after intracardiac injection of human breast cancer MDA-MB-231 cells. Nude mice treated with zoledronic acid at early time points showed a lower incidence of bone metastases than did vehicle-treated nude mice, but these differences were not statistically significant. Only 37.5% of mice treated with zoledronic acid at the time of tumor cell inoculation developed bone metastases compared to over 51.8% of mice receiving vehicle alone (P = 0.304). Cell count of apoptosis confirmed by immunohistochemical staining in metastatic bone tissue significantly increased in the zoledronic acid-treated groups compared to non-treated group (1,018.3 vs 282.0; P = 0.046). However, metastatic tumor cells, which invade soft tissue around the bone, did not show extensive apoptosis; there were no differences between the zoledronic acid-treated and control groups. These results suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in the bone and could therefore reduce metastatic tumor burden. These results support the use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.

AB - Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients with bone metastasis. We evaluated the effects of zoledronic acid, a third generation, nitrogen-containing bisphosphonate, to prevent bone metastasis in breast cancer. Zoledronic acid or vehicle alone was administered to nude mice either simultaneously or after intracardiac injection of human breast cancer MDA-MB-231 cells. Nude mice treated with zoledronic acid at early time points showed a lower incidence of bone metastases than did vehicle-treated nude mice, but these differences were not statistically significant. Only 37.5% of mice treated with zoledronic acid at the time of tumor cell inoculation developed bone metastases compared to over 51.8% of mice receiving vehicle alone (P = 0.304). Cell count of apoptosis confirmed by immunohistochemical staining in metastatic bone tissue significantly increased in the zoledronic acid-treated groups compared to non-treated group (1,018.3 vs 282.0; P = 0.046). However, metastatic tumor cells, which invade soft tissue around the bone, did not show extensive apoptosis; there were no differences between the zoledronic acid-treated and control groups. These results suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in the bone and could therefore reduce metastatic tumor burden. These results support the use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84863015686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863015686&partnerID=8YFLogxK

U2 - 10.3346/jkms.2011.26.12.1569

DO - 10.3346/jkms.2011.26.12.1569

M3 - Article

C2 - 22147993

AN - SCOPUS:84863015686

VL - 26

SP - 1569

EP - 1575

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 12

ER -